Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market ...

Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market ...

We think Vertex, with Journavx, and Lilly, with STC-004, are well-placed to capture a share of the broad market of pain management in the coming years ...

The acquisition includes STC-004, a Phase II-ready Nav1.8 sodium channel inhibitor with the potential to be a next-generation, non-addictive pain therapy. Under the terms of the deal, SiteOne ...

"Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies." ...

The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering from ...

Eli Lilly is making waves by acquiring SiteOne Therapeutics for up to $1 billion, eyeing a non-opioid chronic pain treatment. This deal centers around STC-004, an innovative drug designed to sidestep ...

The centerpiece of the acquisition is STC-004, a Phase 2-ready Nav1.8 inhibitor that could offer significant relief to patients suffering from chronic pain without the risks associated with addictive ...

The acquisition centers on SiteOne’s STC-004, a Phase 2 ready Nav1.8 inhibitor, which is being researched as a potential new treatment for chronic pain. Mark Mintun, Lilly’s group vice president of ...